RYTM

Rhythm Pharmaceuticals Inc

RYTM, USA

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. The company was founded in 2008 and is headquartered in Boston, Massachusetts.

https://rhythmtx.com

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
RYTM
stock
RYTM

RYTM Stock: Canaccord Genuity Raises Price Target to $141, Maint GuruFocus

Read more →
RYTM
stock
RYTM

Goldman Sachs Raises Price Target for RYTM to $157, Maintains Buy Rating | RYTM Stock News GuruFocus

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

STRONG BUY

Target Price:

$127

Analyst Picks

Strong Buy

8

Buy

4

Hold

0

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very High

49.10

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-35.55 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-10.44 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very Low

-51.90 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

Very Low

2.41

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 101.85% of the total shares of Rhythm Pharmaceuticals Inc

1.

BlackRock Inc

(9.4362%)

since

2025/06/30

2.

Baker Bros Advisors LP

(8.4379%)

since

2025/06/30

3.

RA Capital Management, LLC

(8.373%)

since

2025/06/30

4.

PRIMECAP Management Company

(7.3442%)

since

2025/06/30

5.

Vanguard Group Inc

(5.4037%)

since

2025/06/30

6.

PRIMECAP Odyssey Aggressive Growth

(4.6538%)

since

2025/06/30

7.

NEA Management Company, LLC

(4.3811%)

since

2025/06/30

8.

Perceptive Advisors LLC

(3.6409%)

since

2025/06/30

9.

Vanguard Total Stock Mkt Idx Inv

(3.0449%)

since

2025/07/31

10.

FMR Inc

(2.941%)

since

2025/06/30

11.

State Street Corp

(2.872%)

since

2025/06/30

12.

Goldman Sachs Group Inc

(2.6102%)

since

2025/06/30

13.

Federated Hermes Inc

(2.5391%)

since

2025/06/30

14.

Westfield Capital Management Company, L.P.

(2.4533%)

since

2025/06/30

15.

PRIMECAP Odyssey Growth

(2.3017%)

since

2025/06/30

16.

HHG PLC

(2.1257%)

since

2025/06/30

17.

T. Rowe Price Associates, Inc.

(2.0196%)

since

2025/06/30

18.

iShares Russell 2000 ETF

(1.9772%)

since

2025/08/31

19.

Geode Capital Management, LLC

(1.9742%)

since

2025/06/30

20.

Driehaus Capital Management LLC

(1.912%)

since

2025/06/30

21.

Polar Capital Holdings PLC

(1.8833%)

since

2025/06/30

22.

Polar Capital Biotech S Inc

(1.882%)

since

2025/07/31

23.

Checkpoint Capital LP

(1.5959%)

since

2025/06/30

24.

Alkeon Capital Management, LLC

(1.5322%)

since

2025/06/30

25.

Rock Springs Capital Management LP

(1.2965%)

since

2025/06/30

26.

Federated Hermes Kaufmann Small Cap Grow

(1.1171%)

since

2025/06/30

27.

Federated Hermes Kaufmann Small Cap A

(1.1171%)

since

2025/06/30

28.

Federated Hermes Kaufmann Growth

(1.1036%)

since

2025/06/30

29.

Federated Hermes Kaufmann R

(1.1036%)

since

2025/06/30

30.

BlackRock Health Sciences Opps Inv A

(1.0394%)

since

2025/07/31

31.

SPDR® S&P Biotech ETF

(0.9485%)

since

2025/08/31

32.

BGF World Healthscience A2

(0.9205%)

since

2025/05/31

33.

Vanguard Institutional Extnd Mkt Idx Tr

(0.8745%)

since

2025/07/31

34.

Fidelity Small Cap Growth

(0.8693%)

since

2025/06/30

35.

Fidelity Small Cap Index

(0.8218%)

since

2025/06/30

36.

ACAP Strategic A

(0.757%)

since

2025/06/30

37.

iShares Russell 2000 Growth ETF

(0.7203%)

since

2025/08/31

38.

T. Rowe Price New Horizons

(0.6762%)

since

2025/07/31

39.

US Small-Cap Growth II Equity Comp

(0.5811%)

since

2025/06/30

40.

JPMorgan Small Cap Growth A

(0.5699%)

since

2025/07/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2025-09-30

EPS Actual

-0.82

EPS Estimate

-0.6874

EPS Difference

-0.1326

Surprise Percent

-19.2901%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Weak Deep Value(1.5)
Defensive
Moderately Defensive(5.5)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
No Clear Moat(2.8)
GARP
Not Attractive for GARP(1.5)
Growth
Weak Growth Prospect(1.5)
Momentum
No Momentum(2.5)
Net Net
Not Undervalued (Net-Net)(2.5)
Quality
Low Quality Business(1)
Value
Overpriced(1.5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.